Standardisation of syndrome differentiation and exploring Chinese herbal medicine use for early breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032497

Enrollment

Unknown

Registered

2020-04-30

Start date

2020-05-01

Completion date

Unknown

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

case series:N/A

Eligibility

Sex/Gender

Female

Age

24 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Patients whose pathology meets the diagnostic criteria of early breast cancer (stage I-III, excluding distant metastasis); 2. Female patients over 18 years old (including 18 years old); 3. Patients with a score of 0-2 in ECoG (Eastern Cooperative Oncology Group); 4. Patients who voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular diseases or mental related diseases; 2. Patients who receive neoadjuvant therapy or chemotherapy, radiotherapy and endocrine therapy at the same time; 3. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
symptoms, signs, syndromes and application of traditional chinese medicine;	—

Countries

China

Contacts

Public ContactQianjun Chen

Guangdong Provincial Hospital of Chinese Medicine

cqj55@163.com+86 18688883505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026